Pharmesis International (BFK) Stock Overview

Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People's Republic of China. The company provides prescribed products and over-the-counter drugs. It offers western medicine products under the Kinna brand, including Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Compound Procaine hydrochloride to treat arteriosclerosi, menopausal symptoms, dyspepsia, and adynamia; Lianpushuangqing for acute inflammation; AFenKa to treat migraine, pain, headache, nasosinusitis, cold, muscle pain, menstrual pain, toothache, and arthritis; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for the rheumatoid arthritis and other rheumatic diseases treatment. The company also provides TCM formulated products under the Longlife brand name comprising Gulin Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice, and clear heat and toxics; and Kang Gu Zeng Sheng for boosting the functions of kidney, as well as for increasing blood circulation and alleviating pain. In addition, it offers health supplement products, such as Mei Li Wei Ta to combat aging process and support bone health for women; Hao Xiu Xi to enhance sleep and regulate blood fats; Hao Zhuang Tai to regulate blood fats and fight fatique; and Qianlieman'an for promoting healthy prostate function and colon health, and supporting urinary function, as well as SHULINGHOU for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness. Further, the company engages in the wholesale of chemical drugs, biological raw products, TCM products, antibiotics, and antibiotic agents. Pharmesis International Ltd. was founded in 1996 and is based in Singapore.